North Immunology lands Nasdaq route and $180m financing through Aethlon merger

Aethlon Medical, Inc. (NASDAQ: AEMD) has agreed to merge with privately held North Immunology, Inc. in an all-stock transaction that will effectively transform the listed company from a Hemopurifier-focused medical therapeutic developer into an immunology biotechnology company centered on NOR-101, a preclinical bispecific antibody for atopic dermatitis. North Immunology, Inc. is simultaneously arranging approximately $180 million of gross private-placement financing, including about $146 million of new cash and conversion of roughly $34 million of outstanding convertible notes, with the combined company expected to have a pro forma equity value of approximately $346.5 million. Following closing, the surviving public company will operate under the North Immunology, Inc. name and is expected to trade on Nasdaq under ticker NRTX. The crucial ownership detail is that pre-merger Aethlon Medical, Inc. shareholders are expected to hold only approximately 4.75% of the combined business, while pre-merger North Immunology, Inc. shareholders, including financing investors, will hold approximately 95.25%.

That economic structure helps explain why the transaction should be viewed more like a reverse merger than a conventional acquisition by Aethlon Medical, Inc. North Immunology, Inc. management will lead the combined organization, NOR-101 becomes the primary development focus and most post-closing ownership belongs to North Immunology, Inc. and the financing syndicate. Legacy Aethlon Medical, Inc. shareholders retain one additional source of potential value through contingent value rights tied to future monetization of the existing Hemopurifier business.

Where does the $180 million private placement actually go?

The headline financing consists of approximately $180 million in gross proceeds to North Immunology, Inc., but roughly $34 million represents conversion of North Immunology, Inc.’s existing convertible promissory notes and associated amounts rather than fresh cash. Approximately $146 million therefore represents new cash capital expected to enter the company. The merger agreement requires at least $175 million of private-placement proceeds as a closing condition, emphasizing that the financing is fundamental to the transaction rather than a separate optional capital raise.

Investors in the financing include Bain Capital Life Sciences, Janus Henderson Investors, Deep Track Capital, Longitude Capital, Soleus Capital, Invus, Farallon-managed funds, Adage Capital Partners and TCGX. North Immunology, Inc. expects the resulting capital to finance operations into the second half of 2028, covering early clinical development of NOR-101 and progression into proof-of-concept studies. The institutional syndicate is strategically important because North Immunology, Inc. is still preclinical and therefore needs investors willing to finance multiple years before meaningful efficacy data emerge.

The pro forma capitalization illustrates where the value sits. Aethlon Medical, Inc.’s existing equity represents only a small percentage of the resulting company, while North Immunology, Inc. and financing investors provide the overwhelming majority of the implied valuation and capital. Existing Aethlon Medical, Inc. shareholders are effectively exchanging control over a cash-constrained clinical company for minority exposure to a much better funded immunology platform plus the CVR tied to the old business.

What is NOR-101 and why is North Immunology, Inc. targeting atopic dermatitis?

NOR-101 is a half-life-extended bispecific antibody designed to inhibit both interleukin-13 and interleukin-18. North Immunology, Inc. argues that existing antibody therapies directed at type 2 inflammatory biology have transformed atopic dermatitis treatment but leave substantial residual disease for many patients because other inflammatory pathways remain active. By targeting IL-13 and IL-18 simultaneously, North Immunology, Inc. hopes to suppress both type 2 and non-type 2 inflammation through one medicine.

The candidate remains preclinical, which makes phrases such as “best in disease” aspirations rather than established clinical conclusions. North Immunology, Inc. has reported a roughly 42-day half-life in non-human primate studies, a property that could potentially support convenient dosing if human pharmacokinetics behave similarly. The first Phase 1a study is expected to begin during the first quarter of 2027, with interim pharmacokinetic and safety data expected around mid-2027.

North Immunology, Inc. plans to progress rapidly thereafter, targeting Phase 1b and Phase 2b development during 2027 and topline data in 2028. That schedule explains why $146 million of fresh financing can be valuable despite the company not yet having human efficacy evidence. The capital is intended to carry NOR-101 across the transition from an attractive biological hypothesis into a clinical asset whose competitive profile can actually be compared with established atopic dermatitis treatments.

What happens to Aethlon Medical, Inc.’s Hemopurifier program?

Aethlon Medical, Inc.’s existing Hemopurifier assets do not become the central operating focus of North Immunology, Inc. Instead, shareholders of Aethlon Medical, Inc. immediately before the merger are expected to receive contingent value rights entitling them to certain net proceeds if the legacy Hemopurifier business is sold, licensed, transferred or otherwise monetized after closing. That structure separates some of the potential legacy value from the 4.75% ownership stake existing investors receive in the combined company.

The CVR is important because Aethlon Medical, Inc. had continued advancing Hemopurifier development before the merger agreement. The company reported early biomarker observations from an Australian Phase 1 oncology study and had treated a participant in the third dose cohort by August. Those observations remain preliminary, and Aethlon Medical, Inc. has not demonstrated commercial viability for the device.

Financial constraints provide further context for the strategic decision. Aethlon Medical, Inc. held only about $4.9 million of cash at June 30 and subsequently raised approximately $4 million in gross proceeds through a public stock offering. First-quarter operating expenses were approximately $1.6 million, leaving Aethlon Medical, Inc. with far less capital than would be required to finance a major independent late-stage development program.

Why did Aethlon Medical, Inc. shares explode 374% despite the tiny ownership percentage?

Aethlon Medical, Inc. shares closed at $6.78 on September 17, up 374.13% from $1.43 the previous session, on extraordinary volume of nearly 92 million shares. The stock traded as high as $9.50 intraday before giving back part of the gain, then declined another 6.93% to $6.31 on September 18. Even after the pullback, the market value assigned to the public shell and its expected combined-company stake had been radically reset.

The move can initially look contradictory because 4.75% is a small ownership position. The pro forma transaction value provides the explanation: 4.75% of a $346.5 million implied equity value equates conceptually to about $16.5 million before considering adjustments, CVR value and future market movements, which aligns closely with the Aethlon Medical, Inc. contribution shown in North Immunology, Inc.’s transaction materials. Investors are therefore pricing the public company relative to a new financing-backed valuation framework rather than its pre-deal Hemopurifier story alone.

That does not make the 374% rally a clinical endorsement of NOR-101. The molecule has not yet been administered to a human patient, the merger requires shareholder and other approvals, and Aethlon Medical, Inc.’s ownership percentage could be reduced if its net cash at closing falls below zero. The stock move reflects transformed corporate economics and speculative expectations around a much better funded biotechnology program.

The transaction is expected to close in the first quarter of 2027. From that point, investors will effectively be evaluating North Immunology, Inc. rather than the old Aethlon Medical, Inc. business. The next durable valuation milestones will come from human pharmacokinetic, safety and efficacy data, not from the mechanics that produced one of the biotechnology sector’s most dramatic single-day stock moves of September.